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Introduction
Even in the absence of extracellular stimulation, receptor tyro-
sine kinase (RTK) phosphorylation is continuously turned over 
in eukaryotic cells (Kleiman et al., 2011). Uncontrolled kinase 
and/or phosphatase activity leads to aberrant signal transduction, 
thus regulation of the opposing catalytic functions is required to 
ensure that downstream response only occurs when an appro-
priate extracellular-stimulating ligand binds. Regulation of the 
RTK fibroblast growth factor receptor 2 (FGFR2) and the SH2 
domain–containing protein tyrosine phosphatase 2 (Shp2) is con-
trolled by the growth factor receptor–bound protein 2 (Grb2).
Previously, we observed that cells stably expressing 
FGFR2 exhibit elevated receptor phosphorylation in the basal 
state (Ahmed et al., 2008; Schüller et al., 2008). In the absence 
of extracellular growth factor stimulus, Grb2 binds to FGFR2 
via its C-terminal SH3 domain (C-SH3; Ahmed et al., 2010; 
Lin et al., 2012). Grb2 is able to form a dimer and recruit two 
receptor molecules into a heterotetramer. In this state at least 
the two activation loop tyrosine residues (Y653 and Y654) 
of FGFR2 are phosphorylated, but no downstream mitogen- 
activated protein (MAP) kinase signaling is observed (Lin et al., 
2012). On engagement of the growth factor by FGFR2, recep-
tor dimerization is stabilized and autophosphorylation is up-
regulated. Grb2 is phosphorylated on a tyrosine residue (Y209) 
by the fully active FGFR2, which results in dissociation from 
the complex with the receptor. Release of the interaction with 
Grb2 permits the FGFR2 kinase domain to access additional 
tyrosine residues on the receptor, and to recruit downstream 
effector proteins required for signal transduction. We also dem-
onstrated in vitro that Grb2 was able to inhibit Shp2-mediated 
FGFR2 activation loop tyrosine dephosphorylation (Ahmed 
et al., 2010). Grb2 therefore exerts pivotal control of receptor 
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regulation and lead to abnormal receptor function and aberrant 
downstream signaling. Thus, rather than being a passive adaptor 
protein, Grb2 is an essential positive and negative regulator 
of receptor phosphorylation and hence ultimately downstream 
signal transduction.
Results
Shp2-mediated dephosphorylation of 
FGFR2 is controlled by Grb2
In an earlier in vitro experiment we demonstrated that Shp2-
mediated dephosphorylation of the FGFR2 activation loop 
tyrosine residues occurs only in the absence of Grb2 (Ahmed 
et al., 2010). This finding was confirmed in a cellular context 
by showing that knocking down the Grb2 concentration in 
three different cell lines results in lower constitutive FGFR2 phos-
phorylation. Stable Grb2-depleted HEK293T cells (80% 
knockdown) overexpressing wild-type FGFR2 with a C-terminal 
GFP fusion tag (WTFGFR2-GFP) were generated using Grb2 
shRNA (Fig. 1 A). In addition, we also generated stable Grb2-
depleted A431 (Fig. 1 B) and Rat-1 (Fig. 1 C) cells that express 
only endogenous FGFR2. The basal level of phosphorylated 
FGFR2 (pFGFR2) was compared between Grb2 knockdown 
cells (Grb2i) and those infected with a scrambled control shRNA 
(Ci). In HEK293T cells overexpressing WTFGFR2-GFP, Grb2 
knockdown resulted in a decrease in the level of basal receptor 
phosphorylation (Fig. 1 A). Similarly, knockdown of Grb2 in 
A431 and Rat-1 cells also led to a measurable decrease in the 
level of endogenous FGFR2 phosphorylation (Fig. 1, B and C). 
It should be noted that in A431 cells the efficiency of Grb2 
knockdown was much higher than that in Rat-1 cells, which is 
reflected in the respective levels of receptor dephosphorylation 
observed between the two cell lines. In addition to the experi-
ments in the Grb2 knockdown background, we used a HEK293T 
cell line overexpressing the oncogenic S252W mutant FGFR2 
(S252WFGFR2). This mutant receptor is incapable of binding to 
Grb2 (Fig. S1 C). In the absence of the Grb2 interaction, basal 
receptor phosphorylation is reduced in a similar way to that 
seen in the Grb2i cells (Fig. S2 A). The observation of decreas-
ing pFGFR2 in all three Grb2 knockdown cell lines, and in the 
cells expressing S252WFGFR2 is consistent with (1) the increased 
access of active phosphatase to the receptor in the absence of 
the inhibitory effect of Grb2, and/or (2) the loss of Grb2–FGFR2 
heterotetramer formation reducing the propensity for basal re-
ceptor phosphorylation.
Knocking down of Shp2 in A431 (Shp2i, Fig. 1 B) in the 
presence of Grb2 shows a small increase in receptor phosphory-
lation under nonstimulated conditions, suggesting that Shp2 is a 
phosphatase for FGFR2 and that Grb2 inhibition of Shp2 activ-
ity in normal cells is not 100% effective. However, to confirm 
that Shp2 is responsible for the dephosphorylation of FGFR2 in 
the absence of Grb2, we measured the effect of a Shp2 inhibitor 
(NSC87877) on the pFGFR2 level in HEK293T cells in which 
Grb2 had been knocked down (Fig. 1 D). NSC87877 is a potent 
inhibitor that is selective for Shp2 over other PTPs (except the 
highly homologous Shp1; Chen et al., 2006). In Grb2i cells the 
concentration of pFGFR2 was reduced, corroborating the data 
phosphorylation–dephosphorylation; however, the mechanistic 
details for this important, constitutive role remain elusive.
Ubiquitously expressed Grb2 forms a heterotetrameric com-
plex with FGFR2 but plays a more familiar role in linking RTKs 
to the MAP kinase signaling pathway (Lowenstein et al., 1992; 
Chardin et al., 1993; Rozakis-Adcock et al., 1993). Grb2 largely 
consists of a central SH2 domain sandwiched between N- and 
C-terminal SH3 domains. Grb2 is a highly abundant protein and 
is able to interact with numerous cellular phospho- and nonphos-
phoproteins through its SH2 and SH3 domains, respectively.
Somatic mutations in FGFR2 have been associated with 
a number of human cancers (Jang et al., 2001; Pollock et al., 
2007; Dutt et al., 2008; Byron et al., 2010), whereas missense 
germline mutations of the fgfr2 gene are seen in congenital 
skeletal disorders (Wilkie et al., 1995; Johnson et al., 2000; 
Yu et al., 2000; Goriely et al., 2010; Turner and Grose, 2010). 
Alternative gene-splicing events provide numerous structural 
variants of FGFR2. C-terminal sequence splicing provides a 
major group of FGFR2 isoforms. Variants that result in dele-
tions of the C-terminal sequence show enhanced transform-
ing activity (Cha et al., 2008) and are expressed in increased 
amounts in gastric, bladder, and stomach cancer cell lines 
(Hattori et al., 1990, 1996; Itoh, et al., 1994; Ishii et al., 1995) 
and in a majority of human breast carcinoma cells (Cha et al., 
2009). Furthermore, point mutations in the C-terminal region 
of FGFR2 have recently been linked with melanoma (Gartside 
et al., 2009). The C terminus of FGFR2 harbors numerous 
sites for the recruitment of downstream signaling effector pro-
teins, thus perturbation of this region of FGFR2 can contribute 
to oncogenesis.
Shp2 (also known as protein tyrosine phosphatase non-
receptor type 11 [PTPN11]) can be recruited by several RTKs 
either directly, or indirectly via auxiliary adaptor proteins 
(Freeman et al., 1992; Feng et al., 1993; Barford and Neel., 1998; 
Grossmann et al., 2010). Its phosphatase activity is thus impor-
tant in regulation of intracellular signaling activity (Holgado-
Madruga et al., 1996; Kouhara et al., 1997; Neel et al., 2010). Shp2 
is auto-inhibited by an intramolecular SH2 domain–mediated 
interaction, displacement of which is necessary to promote 
catalytic activity (Hof et al., 1998). Although there is some con-
jecture in the field, it has been reported that activated RTKs 
phosphorylate tyrosine 542 (Y542) on Shp2, which appears to 
enhance phosphatase activity (Lu et al., 2001; Araki et al., 2003; 
Keilhack et al., 2005).
Here we provide the mechanism for the control by Grb2 
of FGFR2 kinase and the Shp2 phosphatase activity in the ab-
sence of extracellular stimulation. Grb2 plays the pivotal role in 
regulating the level of FGFR2 phosphorylation through con-
trolled inhibition of (1) the kinase activity of the receptor neces-
sary for full autophosphorylation and signal transduction (Lin 
et al., 2012); (2) the kinase activity of the receptor required to 
phosphorylate Shp2; and (3) the phosphatase activity of Shp2 
directed at FGFR2. Our data demonstrate the mutual depen-
dency of FGFR2 and Shp2 on Grb2 to dictate their respective 
cellular activity and maintain homeostasis of receptor phos-
phorylation in the nonstimulated state. Perturbation of this con-
trol in the nonstimulated cell can disrupt appropriate FGFR2 
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Colocalization and binding were imaged under serum-starved 
conditions (Fig. 2, A–D). As expected, in nonstimulated cells 
FGFR2-GFP is localized primarily in the plasma membrane, 
whereas Shp2-RFP displays a diffused distribution (Fig. 2, 
A–D). In both the wild-type Ci control cells and Grb2i cells no 
significant interaction between FGFR2-GFP and Shp2-RFP 
was seen (Fig. 2, A and B, basal), as shown by the population 
distribution of the fluorescence lifetimes being largely at longer 
lifetimes (right shifted) than that of isolated GFP at 2.0 ns (indi-
cated by the vertical line through the right-hand panels), i.e., 
there is no evidence of FRET between the GFP and RFP fluor-
ophores. Because the FGFR2–Shp2 interaction might only 
occur on transient catalytic turnover of receptor substrate phos-
photyrosine residues, we repeated the FLIM experiments in cells 
transfected with the Shp2 C459S “substrate-trapping” mutant, 
the catalytic activity of which is compromised, and the phos-
phatase domain interacts with the substrate in an equilibrium-
binding mode only (Agazie and Hayman, 2003; Blanchetot 
et al., 2005). Again we see no significant evidence of binding 
between receptor and phosphatase in the presence of Grb2 
(Fig. 2 C). However, in the absence of Grb2, binding of Shp2 
C459S mutant to FGFR2 can be observed (Fig. 2 D; peak in 
right-hand panel shifts to left of the vertical line, i.e., to shorter 
lifetimes resulting from FRET between GFP and RFP). These 
data support a model in which the presence of Grb2 inhibits 
direct binding of Shp2 to the receptor. The presence of Grb2 
bound to the C terminus of FGFR2 may sterically hinder access 
of the phosphatase to its cognate site, and/or inhibit the recep-
tor kinase activity toward a tyrosine residue(s) required for 
Shp2 recognition.
By way of comparison, we show that on stimulation of 
FGFR2 with FGF9 the population of Shp2 and FGFR2 complex 
increases significantly (Fig. 2, E and F; see population shifts to 
shorter lifetimes in right-hand panels). This is consistent with 
the model in which stimulation and up-regulation of kinase 
activity of FGFR2 results in dissociation of Grb2 (Lin et al., 
2012), promoting formation of the Shp2–FGFR2 complex.
FGFR2-mediated phosphorylation of Shp2 
is controlled by Grb2
Phosphatase activity has been reported to be enhanced by tyrosyl 
phosphorylation on Shp2. Shp2 has two C-terminally located 
tyrosine residues (Y542 and Y580) that have been implicated 
in the mechanism for release of the auto-inhibited state of the 
phosphatase (Lu et al., 2001). It has been suggested that phos-
phorylation of one (or both) of these tyrosines is important in 
Shp2 activation, although there has been no clear demonstration 
that tyrosyl phosphorylation of Shp2 is necessary to initiate sig-
naling. However, phosphorylation of Shp2 does appear to be in-
volved in effecting downstream extracellular signal–regulated 
kinase (ERK) activation (Araki et al., 2003).
RTKs have been shown to phosphorylate Shp2, although 
a role for FGFR2 in this activity has not been reported. To dem-
onstrate that Shp2 is a substrate for FGFR2, HEK293T Ci serum-
starved cells were incubated with and without FGFR2 kinase 
inhibitor (SU5402) for 2 h. Fig. 3 A shows in the Ci nonstimu-
lated cells there is a background level of phosphorylated Y542 
from Fig. 1, A–C. Incubation with the Shp2 inhibitor resulted 
in an increase in pFGFR2 to levels similar to those seen in Ci 
cells (Fig. 1 D). Again in HEK293T cells overexpressing the 
S252WFGFR2 mutant receptor, which is unable to bind Grb2, in-
cubation with NSC87877 resulted in increased basal receptor 
phosphorylation (Fig. S2, B–D). These data strongly suggest 
that Grb2 constitutively inhibits the ability of Shp2 to dephos-
phorylate the receptor. Furthermore, it also infers that a basal 
level of FGFR2 phosphorylation prevails even in the absence 
of Grb2. Thus, it appears that in wild-type cells Grb2 serves to 
stabilize and control this FGFR2 kinase activity through hetero-
tetramer formation.
Grb2 inhibits direct complex formation 
between FGFR2 and Shp2
Having demonstrated that dephosphorylation of FGFR2 by Shp2 
is impeded in the presence of Grb2, we investigated whether 
Grb2 was inhibiting the formation of a direct equilibrium com-
plex between the receptor and phosphatase. Formation of a sta-
ble complex is likely to be important in directing phosphatase 
activity toward FGFR2. To measure direct binding of Shp2 to 
FGFR2 we used fluorescence lifetime imaging microscopy 
(FLIM) to detect stable complexes through fluorescence reso-
nance energy transfer (FRET) between fluorophore-tagged pro-
teins. RFP-tagged Shp2 was transfected into HEK293T Ci 
and Grb2i cells that were stably overexpressing FGFR2-GFP. 
Figure 1. Knockdown of Grb2 and Shp2 reveal that the level of WTFGFR2 
phosphorylation is controlled by Grb2. (A) Total HEK293T cell lysates were 
immunoblotted with anti-pFGFR antibody (top), and reprobed for total FGFR 
(middle) and Grb2 (bottom). Anti-pFGFR2 antibody is specific for A loop 
residues Y653 and Y654. (B) Cell lysates of overnight serum-staved stable 
A431 cells containing control shRNA (Ci), Grb2-shRNA (Grb2i), or Shp2-
shRNA (Shp2i) were analyzed for FGFR2 phosphorylation as above. Only 
the nonstimulated state is shown (i.e., each lane is duplicated). Numbers 
on pFGFR2 panel are normalized intensity pFGFR2/total FGFR2. (C) Analy-
sis of FGFR2 phosphorylation in Rat-1 fibroblast cells with control shRNA 
(Ci) and Grb2-shRNA (Grb2i) as above. Only the nonstimulated state was 
investigated (i.e., each lane is duplicated). (D) Inhibition of Shp2 in Grb2 
knockdown cells restores basal receptor phosphorylation. Serum-starved 
WT-Ci and WT-Grb2i cells were incubated with 50 µM NSC87877 for 
4 h and the resultant cell lysates were analyzed by Western blotting with 
anti-pFGFR2 antibody, Shp2 pY542-specific antibody, and anti-Grb2 anti-
body. The immunoblot was stripped and reprobed for total FGFR2 and 
Shp2 as the loading control. The numbers on the pFGFR2 panel represent 
normalized intensity pFGFR2/total FGFR2.
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FGFR2 kinase activity is switched on in the nonstimulated 
state, as demonstrated by phosphorylation of activation loop 
tyrosine residues Y653/Y654 (Fig. 1, A–C). Here we confirm 
the occurrence of this activity under nonstimulated conditions 
by the observation of a higher molecular weight band corre-
sponding to phosphorylated Grb2 (also described by Lin et al., 
2012) that is apparent in HEK293T cells overexpressing FGFR2 
(Fig. 4 A). This phosphorylation of Grb2 can be attributed to 
FGFR2 kinase activity because the higher molecular weight 
band is absent in wild-type HEK293T cells, which do not ex-
press endogenous FGFR2 kinase. Thus, the phosphorylation 
and subsequent dissociation of Grb2 can occur in the nonstimu-
lated state.
Accumulation of increasing cellular concentrations of 
pGrb2 (which cannot bind receptor) would result in release of 
the controlling influence of Grb2 on FGFR2 kinase activity; 
thus, dephosphorylation of Grb2 is required to maintain cellular 
homeostasis in the nonstimulated state. Using an in vitro experi-
ment in which purified full-length wild-type Shp2 (WTShp2) 
was incubated with phosphorylated C-SH3 domain of Grb2 we 
demonstrated that Shp2 can dephosphorylate Grb2 on residue 
(pY542) on Shp2. In the presence of the FGFR2 inhibitor the 
concentration of pY542 is reduced. This strongly suggests that 
Shp2 is a substrate for basal FGFR2 kinase activity and thus the 
receptor is able to enhance phosphatase activity. We have thus 
identified a catalytic cycle around Shp2 phosphatase dephos-
phorylating FGFR2, and FGFR2 kinase phosphorylating Shp2.
To assess whether constitutive FGFR2 phosphorylation of 
Shp2 is under the control Grb2, phosphorylation of Y542 on 
Shp2 was investigated in the presence or absence of Grb2. In 
A431-Grb2i cells the concentration of phosphorylated of Shp2 
is elevated by 2.5-fold compared with A431-Ci cells in the 
nonstimulated state (Fig. 3, B and C). The presence of Grb2 
therefore has an inhibitory effect on FGFR2-derived phos-
phorylation of the phosphatase.
Shp2 binds to and dephosphorylates Grb2
Previously we reported that Grb2 can be phosphorylated by 
FGFR2. Phosphorylation of Y209 in the C-terminal SH3 do-
main (C-SH3) of Grb2 in the interface with FGFR2 sterically 
and/or electrostatically hinders complex formation, resulting in 
the release of phosphorylated Grb2 (pGrb2; Lin et al., 2012). 
Figure 2. Grb2 inhibits the interaction of Shp2 with FGFR2. 
(A) FLIM analysis of the FRET between the FGFR2-GFP and 
RFP-Shp2. In the control (WT-Ci) serum-starved cells no inter-
action between FGFR2 and Shp2 was observed in the basal 
state. The mean FRET lifetime is 2.0 ns (line in right-hand 
panel), which corresponds to the mean lifetime for isolated 
GFP. No apparent interaction between FGFR2 and Shp2 in 
WT-Grb2i cells (B), or WT-Ci cells transfected with the RFP-
tagged substrate-trapping C459S Shp2 mutant (C). Inter-
action between FGFR2 and Shp2 is observed in the Grb2i 
the substrate-trapping C459S mutant (D). Stimulating cells that 
contain WTShp2 or C459S mutant Shp2 with FGF9 results in 
clear binding between FGFR2 and Shp2 after 15 min (E and F), 
respectively. Bar, 10 µm.
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level of interaction between Shp2 and Grb2 is observed, 
as shown by slight left shift in peak position and overall distri-
bution under the curve compared with CFP alone (line drawn 
at the lifetime of isolated CFP, 2.2 nm; see right-hand panels 
of Fig. 5, A and B). The shift to shorter lifetimes is more pro-
nounced in the stimulated state, presumably due to the presence 
of increased concentrations of phosphorylated Shp2 (Fig. 5 B). 
The nonphosphorylatable Y542F Shp2 mutant showed less abil-
ity to bind Grb2, even under stimulated cellular conditions 
(Fig. 5 C). This demonstrates that binding to, and hence dephos-
phorylation of Grb2 by Shp2 is, at least in part, mediated by the 
binding of pY542. Interestingly, the substrate-trapping C459S 
mutant shows significant binding in the basal state (almost 
the entire population of tagged protein is left shifted; Fig. 5 D). 
Because the substrate-trapping mutant binds to the protein in an 
equilibrium mode, the observed enhanced population of com-
plex, compared with that in the presence of WTShp2, suggests 
that wild-type phosphatase is turning over pGrb2.
The above observations are important because they con-
firm the cycling of Grb2 between its FGFR2-phosphorylated 
state and Shp2-dephosphorylated state. This cycling of Grb2 
is fundamental to the maintenance of homeostasis of FGFR2 
kinase activity. The rate of cycling maintains a steady-state level 
of the phosphorylation of Grb2 and ensures that the phosphory-
lated receptor population is controlled and incapable of effect-
ing a downstream response. On exposure to an extracellular 
ligand this cycling is presumably pushed toward increased con-
centrations of pGrb2 and hence expanding the population of 
up-regulated FGFR2 molecules.
Y209 (Fig. 4 B). There are two phosphorylatable tyrosines on 
C-SH3 (Y160 and Y209; Lin et al., 2012). To assess whether 
Shp2 phosphatase activity was specific for either site we indi-
vidually mutated each of these residues to a nonphosphorylat-
able phenylalanine. Fig. 4 B shows that the amount of pGrb2 
of the Y160F decreases in the presence of Shp2, but not in the 
Y209F mutant. This result shows that Shp2 can dephosphory-
late the C-SH3 domain of Grb2 and is specific for pY209.
To confirm phosphatase activity of Shp2 toward pGrb2 in 
a cellular context, HEK293T cells were cotransfected with 
GFP-FGFR2 and strep-tagged Grb2 (strep-Grb2) and incubated 
with either an FGFR2 kinase inhibitor (SU5402) or a Shp2 
inhibitor (NSC87877), and the level of pGrb2 was determined 
(Fig. 4 C). Under nonstimulated conditions, in the absence of 
either inhibitor we observed the presence of a low level of 
pGrb2. pGrb2 is not observed in the presence of the kinase in-
hibitor, confirming that the basal FGFR2 kinase activity is 
required for Grb2 phosphorylation. Inhibition of the phospha-
tase resulted in increased concentrations of pGrb2 compared 
with when the enzyme is uninhibited.
Having established that Grb2 is a substrate for Shp2, we 
investigated the mechanism by which the phosphatase is re-
cruited. Because Shp2 phosphorylated on Y542 has been previ-
ously reported to bind Grb2 and in doing so affect auto-inhibition 
of the phosphatase domain (Lu et al., 2001), we confirmed that 
this was important for complex formation between these two 
proteins in cells. FLIM data on A431 cells expressing N-terminal 
CFP-tagged Grb2 (CFP-Grb2) and N-terminal RFP-tagged 
Shp2 (RFP-Shp2) reveal that in the nonstimulated state a low 
Figure 3. Shp2 phosphorylation by FGFR2 is inhibited by 
Grb2. (A) Serum-starved HEK293T cells were incubated with 
30 µM FGFR inhibitor (SU5402) for 2 h and then either stimu-
lated with 10 ng/ml FGF9 for 15 min or left untreated. Cell 
lysates were prepared and analyzed by Western blotting 
with the indicated antibody. Anti-pFGFR and anti-Y542 on 
Shp2 antibodies were used to evaluate phosphorylation of 
proteins. The immunoblot was stripped and reprobed with a 
pan-antibody to determine total protein level. (B) Comparison 
of ligand-stimulated Shp2 phosphorylation between A431-Ci 
and A431-Grb2i cells in nonstimulated and on stimulation 
by FGF2 or FGF9 for 1 h. Shp2 phosphorylation was de-
tected with anti-pY542 antibody (top). The immunoblot was 
reprobed for total Shp2 as a loading control (middle) and 
with Grb2 (bottom). (C) Densitometric quantification of basal 
state Shp2 phosphorylation levels in A431 cells in control 
shRNA (A431-Ci) and Grb2-shRNA (A431-Grb2i). Error bars 
represent SD, n = 7.
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To demonstrate the cycling of Grb2 between the receptor-
bound/dephosphorylated state and the unbound/phosphory-
lated state we used an in vitro FRET-based spectroscopic assay 
(Fig. 6 A). The cytoplasmic region of FGFR2 (FGFR2cyto resi-
dues 400–821) and full-length Grb2 N-terminally labeled with 
GFP and RFP fusion proteins, respectively, were expressed and 
purified from Escherichia coli. Initially the fluorescence lifetime 
of isolated GFP-FGFR2 was measured (2.64 ns; Fig. 6 B). 
On adding RFP-Grb2 the fluorescence lifetime in solution 
was measured as they formed the complex in which two recep-
tor molecules were recruited to the Grb2 dimer (Fig. 6 A and 
Fig. S3; Lin et al., 2012). The formation of the complex results 
in FRET between the GFP and RFP fluorophores, and hence, a 
decrease in the fluorescence lifetime. ATP/Mg2+ was added to 
activate the FGFR2 kinase and the fluorescence lifetimes were 
measured at given time points. The lifetime was seen to in-
crease as a consequence of the reduction in direct interaction 
between receptor and adaptor protein as Grb2 is phosphory-
lated by the activated RTK (Fig. 6 B). The lifetime reaches a 
steady state as the concentration of pGrb2 maximizes (2.64 ns). 
Shp2 was then added to the solution of FGFR2cyto and Grb2 
(Fig. 6 A) and the lifetime was recorded. The presence of the 
phosphatase results in the decrease in the fluorescence lifetime 
of GFP-FGFR2cyto due to FRET as the concentration of pGrb2 
is reduced and the resulting dephosphorylated Grb2 binds to the 
receptor (Fig. 6, A and B). These in vitro data mirror the observa-
tions in cells described in Fig. 4 by reproducing the interactions 
and turnover of Grb2 phosphorylation in the presence of kinase 
and phosphatase.
By way of additional confirmation that Grb2 was a sub-
strate for Shp2 we used the substrate-trapping C459S mutant 
of Shp2 in the fluorescence spectroscopic assay. This mutant 
has no inherent catalytic activity, and hence Grb2 should not be 
dephosphorylated in its presence. The addition of this mutant 
results in no reduction in the fluorescence lifetime, consistent with 
no recovery of the Grb2–FGFR2 complex (Fig. 6 B). Further-
more, to confirm the requirement of pY542 to promote phos-
phatase activity against Grb2 we used the nonphosphorylatable 
Y542F mutant Shp2 in place of WTShp2. In this case the recov-
ery of the Grb2–FGFR2 complex was abrogated (the fluores-
cence lifetime remains at 2.64 ns; Fig. 6 C), reflecting the 
reduction in the binding of the mutant Shp2 to Grb2 and hence 
reduced dephosphorylation of Grb2.
We confirmed these observations using the independent 
approach of time-correlated single-photon counting (TCSPC) 
to measure the GFP-FGFR2cyto lifetime. This experiment mea-
sures FRET between the RFP-Grb2 and FGFR2-GFP fluor-
ophore fusion tags in a similar way to the previous experiment; 
however, rather than measuring one lifetime at a specific wave-
length, this method uses a dicrotic filter to detect fluorescence 
emission over a range of wavelengths. The data are measured 
and presented as a percentage of the total population of inter-
actions (Fig. 6 C and Fig. S3). The FLIM data for the interaction 
between FGFR2cyto and Grb2 in the presence of WTShp2 and the 
C459S and Y542F mutants was entirely consistent with the 
spectroscopic data. Interestingly, after an extended period (18 h) 
in the presence of the Y542F Shp2 mutant, the percentage of 
Figure 4. Shp2 dephosphorylates Grb2. (A) Wild-type or FGFR2 stably 
transfected HEK293T were starved overnight, then stimulated using 10 ng/ml 
FGF9 for either 15 or 60 min. Cells were lysed in the presence of prote-
ase and phosphatase inhibitors. 50 µg of total cell lysate were used for 
immunoblotting studies. Phosphorylation of FGFR2 was examined using 
anti-pFGFR2 (first panel). To examine the Grb2 phosphorylation states in 
the absence or presence of FGFR2 expression, 1 mg of total cell lysates 
were used for immunoprecipitation using an anti-Grb2 antibody, and 
probed with an anti-Grb2 antibody. The immunoprecipitated Grb2 from 
FGFR2-overexpressing cells show multiple bands (both serum starved and 
FGF9 stimulated), suggesting the high molecular weight species is tyrosine-
phosphorylated Grb2, which is only phosphorylated in the presence of 
FGFR2. (B) Recombinant Grb2 C-SH3 mutants (Y160F, left; Y209F, right) 
were expressed and purified from E. coli and incubated with pure FGFR2 
cytoplasmic domain in a 1:1 molar ratio in the presence of ATP and MgCl2 
at room temperature for 1 h. Recombinant GST-fused pShp2 was obtained 
via the same protocol. A general anti-pY antibody was used to examine the 
phosphorylation state of FGFR2-phosphorylated Shp2 (lanes 4, 6, 10, and 
12; panel 1) and Grb2 C-SH3 domains (lanes 2 and 8; panel 4). A specific 
anti-pY542 Shp2 antibody was also used to confirm that Y542 of Shp2 is 
phosphorylated. A pool of both proteins was dephosphorylated by mixing 
phosphatase (either pShp2 or Shp2) with phosphorylated protein substrates 
(either pGrb2 C-SH3 Y160F or phospho-Grb2 C-SH3 Y209F) at 4°C over-
night. The anti-pY blot shows only the pGrb2 C-SH3 Y160F can be dephos-
phorylated by both pShp2 and Shp2 (lanes 5 and 6; panel 4). However, 
the phosphorylation state of pGrb2 C-SH3 Y209F is not affected by Shp2, 
suggesting that the Y209 is the target of Shp2. A total Shp2 antibody (panel 3) 
and total Grb2 antibody (panel 5) were used to confirm equal protein 
loading. (C) HEK293T cells were cotransfected with FGFR2-GFP and Grb2-
strep-tag. After 48 h cells were starved for 4 h and incubated with either 
FGFR-specific inhibitor (50 µM SU5402) or Shp2-specific inhibitor (100 µM 
NSC87877) for 1 h. Cell lysates were subjected to affinity purification 
using strep-tactin agarose beads and immunoblotted with anti-pY antibody 
(top) followed by anti-Grb2 antibody (bottom).
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MAP kinase pathway once cells are stimulated). However, 
Grb2-depleted HEK293T and A431 cells do display lower levels 
of growth factor–stimulated MAP kinase activity as reflected 
in levels of phosphorylated ERK (pERK; Fig. 7, A, C, and D; 
Fig. S4, A and C). One explanation for this could be that the 
binding of Grb2 to FGFR2 stabilizes receptor dimers, increas-
ing the probability of active signaling on growth factor stimula-
tion. This obviously would not occur in the absence of Grb2. 
Another possibility is that in the absence of Grb2, ligand-
 activated receptors are rapidly and concomitantly deactivated 
by Shp2, rendering them signaling incompetent. This would 
result in reduced FGF-stimulated MAP kinase activation. We 
investigated this latter hypothesis using the Shp2-specific inhib-
itor to demonstrate that, if Shp2 is responsible for deactivating 
FGFR2 in Grb2i cells, then its inhibition would allow MAP 
interactions increases. This is presumably the result of phospha-
tase activity that still occurs, but the rate is significantly reduced 
in the absence of the amplifying effect of the pY542 interaction 
with Grb2.
Shp2 inhibition restores MAP kinase 
activity in Grb2 knockdown cells
The focus of this work is on the cycling of kinase and phospha-
tase activity under the control of Grb2 in the nonstimulated 
state. However, this control could ultimately have an effect on 
signal transduction once the cells are exposed to growth factor. 
The general viability of Grb2 knockdown cells indicates some 
of the primary functions generally associated with the presence 
of Grb2 in these cells are still intact (e.g., the reduction in over-
all Grb2 concentration does not abrogate signaling through the 
Figure 5. Interaction between Grb2 and 
Shp2. CFP-Grb2 and RFP-Shp2 colocalization 
and direct interaction measurement using FLIM 
in A431 cells. (A) Control lifetime measurement 
for CFP alone. (B) Interaction of CFP-Grb2 with 
RFP-tagged wild-type Shp2 (RFP-WTShp2) at 
basal and after 20 ng/ml FGF9 stimulation. 
(C) Co-localization and direct interaction of 
Y542F mutant Shp2 with CFP-Grb2 at basal 
and after FGF9 stimulation. (D) Constitutive 
interaction of the C459S substrate-trapping 
Shp2 mutant with Grb2. A left-shifted peak rel-
ative to the line drawn along 2.2 ns indicates 
a binding. A peak centered on the 2.2 ns line 
indicates nonbinding. Bar, 20 µM.
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and MAP kinase activation, as manifested by phosphorylation 
ERK (Fig. 2, A and C), were monitored under basal conditions 
and after FGF9 stimulation. The results of these experiments 
show that inhibition of Shp2 in Grb2 knockdown cells does 
indeed restore FGF9-stimulated pERK (Fig. 7, A and C). Further-
more, decreased WTFGFR2 phosphorylation in Grb2i cells can 
be rescued by Shp2 inhibition (Fig. 7, A and B). Shp2 inhibition 
in Grb2-depleted A431 cells also leads to increased receptor 
phosphorylation and restoration of the FGF-stimulated MAP 
kinase response (Fig. 7, D and E). However, Shp2 inhibition 
elicits little effect in EGF-stimulated MAP kinase, which re-
mains unchanged (Fig. 7 F and Fig. S4 B). This therefore pro-
vides further evidence that Grb2 is an inhibitor of Shp2 in 
FGFR2 signaling, and in the absence of Grb2, Shp2 inhibition 
limits receptor activation and downstream signaling. Importantly, 
the Shp2 inhibitor pretreatment increases basal receptor phos-
phorylation, eliciting a significant downstream MAP kinase 
response. This increase in receptor phosphorylation appears 
significantly higher than the specific FGF-induced receptor 
phosphorylation that restored the downstream MAP kinase 
response (Fig. 7). This observation is important because it em-
phasizes that receptor phosphorylation alone is not sufficient for 
signal transduction.
Discussion
The constitutive turnover of RTK phosphorylation requires 
control mechanisms to abrogate the possibility of aberrant sig-
nal transduction. This can be achieved by controlling kinase 
activity, blocking the attainment of the fully active state, and 
inhibiting recruitment of downstream effector proteins to the 
RTK. The data reported herein establish a role for Grb2 in which 
it applies a controlling influence over the basal kinase activity 
of FGFR2 and inhibits Shp2-mediated receptor dephosphory-
lation. This central control exerted by Grb2 can be represented 
by the cycle of contributing catalytic activity shown in Fig. 8 
and summarized below.
Our recent findings revealed that under nonstimulated 
conditions, dimeric Grb2 can bind to two receptor molecules 
resulting in partial phosphorylation of FGFR2 including activa-
tion loop tyrosine residues (Lin et al., 2012; Fig. 8 A). In forming 
this heterotetrameric complex Grb2 inhibits both the dephos-
phorylation of FGFR2 by Shp2 and the phosphorylation of 
Shp2 by FGFR2 (Fig. 8, B and C, respectively). The inhibition 
of the dephosphorylation of partially phosphorylated FGFR2 
(Fig. 8 B) can be demonstrated in cells in which Grb2 expres-
sion has been knocked down which show negligible basal 
receptor phosphorylation (Fig. 1). In the absence of Grb2, Shp2 
is able to interact with FGFR2. This results in receptor dephos-
phorylation. As a result, inhibition of Shp2 under these con-
ditions results in the recovery of the phosphorylated receptor 
(Fig. 1 D and Fig. 7). Not only does this confirm an inhibitory 
role for Grb2 on phosphatase activity, but it also suggests that 
an inherent background phosphorylation of FGFR2 occurs even 
in the absence of Grb2 in nonstimulated cells. We show that 
inhibition of Shp2 activity is likely to result from the inability of 
Shp2 to bind to the receptor in the presence of the Grb2–FGFR2 
Figure 6. In vitro demonstration of catalytic cycling of FGFR2 and Shp2 
in the presence of Grb2. (A) Schematic of interactions performed in vitro 
to demonstrate catalytic activity of FGFR2 and Shp2 on Grb2. Mixing 
FGFR2cyto (blue) with Grb2 (red) promotes the formation of a heterotetra-
meric complex (Lin et al., 2012). Addition of ATP and MgCl2 to this results 
in phosphorylation of FGFR2 and Grb2 (green circle). Addition of Shp2 
(orange) results in dephosphorylation of FGFR2 and Grb2 (blue line). The 
heterotetrameric complex is recovered under these conditions. (B) Fluor-
escence lifetime measurement between GFP-FGFR2cyto and RFP-Grb2 as 
a function of time. The first point corresponds to the fluorescence lifetime 
for isolated GFP-FGFR2 (black arrow). On addition of Grb2 (red arrow) 
a heterotetrameric complex between Grb2 and FGFR2 forms. This results 
in FRET between the GFP and RFP and the concomitant reduction in fluor-
escence lifetime. On addition of ATP/Mg2+ (purple arrow) up-regulation 
of the RTK ensues and Y209 on Grb2 becomes phosphorylated and the 
FGFR2–Grb2 complex dissociates. The lifetime increases, reflecting reduc-
tion in complex concentration and the accumulation of pGrb2. After 80 min 
Shp2 was added (orange arrow). At this point clear reassociation of 
Grb2 and FGFR2 is observed as Grb2 is dephosphorylated in the presence 
of Shp2 and consequently the fluorescence lifetime decreases (blue line on 
graph). Replacing WTShp2 with the Y542F (red line) or C459S (green line) 
mutant results in no immediate reduction in lifetime, confirming that the 
FGFR2–Grb2 complex is not rescued by adding these compromised phos-
phatases. (C) Measurement of FRET between GFP-FGFR2cyto (Cyto) and 
RFP-Grb2 in solution using FLIM. Cyto alone is GFP-FGFR2cyto and repre-
sents the background false-positive percentage FRET readout. Cyto+Grb2 
is the population of molecules undergoing FRET when RFP-Grb2 is present. 
Cyto+Grb2+ATP is the population of GFP-FGFR2cyto undergoing FRET with 
RFP-Grb2 when the FGFR2 kinase was activated. Shp2 30 min and 18 h 
represent the reestablishment of GFP-FGFR2cyto/RFP-Grb2 complex in the 
presence of wild-type (blue line), Y542F (red line), and C459S (green line) 
mutant Shp2 as a function of time.
kinase pathway activation to be restored to its normal level. 
The control Ci and Grb2i HEK293T cells were treated with the 
Shp2 inhibitor (NSC87877) and receptor phosphorylation level 
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down-regulated. This mutually dependent network of enzymatic 
activity is in homeostatic state, which is incapable of signal 
transduction. Addition of extracellular growth factor perturbs this 
state, promoting receptor kinase activity leading to the dissocia-
tion of Grb2 and resulting increased concentration of unfettered 
FGFR2 capable of recruitment of early signaling complex pro-
teins and downstream response (O’Rourke and Ladbury, 2003). 
An additional outcome of up-regulated receptor activity is 
phosphorylation of Shp2, increasing its activity toward both 
FGFR2 and Grb2. Increased populations of dephosphorylated 
Grb2 and hence Grb2–FGFR2 complex restores the system to 
its constitutive homeostatic state.
In a Grb2 knockdown background loss of the Grb2–FGFR2 
interaction leads to reduced receptor phosphorylation. This 
might mimic the effect of oncogenic mutations/deletions of 
FGFR2, which potentially abrogate Grb2–FGFR2 complex 
formation. Although knockdown of Grb2 concentration is likely 
to impinge on its recruitment to the son-of-sevenless (Sos) protein 
and hence affect MAP kinase pathway activation, Grb2 knock-
down cells are still capable of eliciting a response on growth 
factor stimulation (Fig. S4). This implies that the FGFR2–Grb2 
complex does not abrogate signaling in the nonstimulated state 
simply because it sequesters Grb2 and thus prevents it from being 
recruited to Sos. This finding is particularly important because, 
for example, a large number of FGFR2 mutations in melanoma 
are described as loss-of-function (Gartside et al., 2009), yet our 
data suggest that this apparent loss-of-function could still be 
oncogenic due to the mutation leading to the loss of receptor 
complex. Knocking down of Grb2 in cells allows Shp2 to inter-
act with the receptor (Fig. 2).
Grb2 also has an effect on Shp2 activity inhibiting the 
phosphorylation of Shp2 by FGFR2 (Fig. 8 C). Knockdown 
of Grb2 elevates Shp2 phosphorylation (Fig. 3, B and C), 
strongly suggesting that the inability of Shp2 to interact directly 
with the receptor in the presence of Grb2 prevents FGFR2 
kinase activity toward Shp2. The role of Grb2 therefore appears 
to be as the pivotal regulator of the phosphorylation of FGFR2 
and the recruitment of Shp2 to its receptor substrate in the non-
stimulated state.
The controlling effect of Grb2 can be relieved by phos-
phorylation of Y209 by FGFR2 (Fig. 8 D). Removal of the in-
fluence of Grb2 on FGFR2 kinase activity promotes Shp2 
phosphorylation. The active phosphatase can then dephos-
phorylate the receptor, and importantly, rescue the inhibitory 
complex with Grb2 by dephosphorylating Y209 (Figs. 5 and 6). 
We confirmed that the phosphorylation of Y542 on Shp2 is im-
portant for binding to, and dephosphorylation of Grb2 (Fig. 6). 
This interlocking cycle of catalytic activity occurs constitutively, 
strongly suggesting a dynamic mechanism whereby there is con-
tinuous cycling of kinase (positive feedback) and phosphatase 
(negative feedback) activity toward FGFR2 phosphorylation. 
This “background cycling” is centrally controlled by Grb2 based 
on the relative apparent concentrations of dephosphorylated/
phosphorylated Grb2, respectively. Under basal conditions, the 
pool of unphosphorylated Grb2 is large and the probability of 
finding it bound to the receptor is high, thus Shp2 activity is 
Figure 7. Grb2 inhibits Shp2 activity toward FGFR2. (A) WT-Ci and WT-Grb2i cells were incubated with serum-free media with or without 50 µM Shp2 
inhibitor NSC87877 overnight, and then either stimulated with 10 ng/ml FGF9 for 15 min or left untreated. Total cell lysates were analyzed by Western 
blotting with the indicated antibody. (B and C) Densitometric quantification of bands from experiments as described in A. Histogram values correspond 
to normalized bands for pFGFR2 against total FGFR2 (B) and pErk against total Erk (C) of three independent experiments. Error bars represent SD. 
(D) A431-Ci and A431-Grb2i cells were serum starved with 50 µM Shp2 inhibitor overnight, then either stimulated with FGF9 or left untreated. 50 µg total 
cell lysates were immunoblotted with indicated antibody. (E) Densitometric quantification of bands from experiments as described in D, where the ratio of 
pERK/total Erk is plotted from three independent experiments. Error bars represent SD. The A431-Ci FGF9/NSC87877 ratio was fixed as 1.0 for each 
experiment. Arrows highlight the comparison of the level of pErk in the control cells after FGF-ligand stimulation and the recovery of this level in the Grb2 
knockdown cells only when stimulated in the presence of Shp2 inhibitor. (F) Shp2 inhibition does not affect EGF-stimulated MAP kinase response in A431 
cells. The experimental procedure is as above except 50 ng/ml EGF was used to stimulate cells for 5 min.
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(Ahmed et al., 2008). Co-immunoprecipitation experiments 
confirm that under nonstimulated conditions FRS2 does not 
bind to FGFR2 (Fig. S1 D). Furthermore, no discernible inter-
action between Shp2 or Grb2 with FRS2 can be observed (Fig. S1, 
E and F), as has been reported for FGFR1 (Hadari et al., 1998). 
In contrast, ligand-induced signal transduction from FGFR2 
and FGFR1 appears to occur predominantly through forma-
tion of an FGFR–FRS2–Shp2 complex (Fig S1, D–F). These 
distinctions between protein recruitment by the receptors could 
partially explain the differences in oncogenic properties of the 
receptors because in some cancers signaling through FGFR2 
and FGFR1 has opposing outcomes for cancer progression 
and metastasis (Korah et al., 2000; Freeman et al., 2003; Xian 
et al., 2007).
This study raises important questions regarding the future 
design of therapeutic agents directed against FGFR2-initiated 
signaling because it highlights the balance between kinase and 
phosphatase activity (see schematic in Fig. S5), which can be 
readily perturbed by inhibitors. Disturbing one aspect of this 
balance through therapeutic interaction could influence regula-
tion of another (Fig. 8). Indeed, understanding the mechanism 
of control of the balance between kinase and phosphatase activ-
ity could suggest novel targets for pharmaceutical intervention. 
For example, synthetic molecules that influence the control 
function of Grb2 might provide innovative drug compounds.
Materials and methods
Reagents
Recombinant human FGF9, FGF2, and EGF were purchased from PeproTech 
or R&D Systems. Antibodies against FGFR2 (C-17), Shp2 (C-18), Grb2 
(C-23) and phosphotyrosine (pY99), as well as Shp2 inhibitor NSC87877 
and FGFR2 inhibitor SU5402, shRNA, and also lentivirus particles for con-
trol (catalog no. sc-108080), Grb2 (catalog no. sc-29335-v), and Shp2 
(catalog no. sc-36488-v) were all purchased from Santa Cruz Biotechnol-
ogy, Inc. The following antibodies were purchased from Cell Signaling 
Technology: pFGFR2 (anti-pY653/654), Shp2 (pY542), pERK, and ERK. 
Anti-GFP goat antibody was purchased from Rockland Immunochemicals. 
Metafectin cell transfection reagents were purchased from Biontex-USA.
Cell culture
HEK-293T, A431, and Rat-1 fibroblast cells were maintained in Dulbecco’s 
modified Eagle’s high glucose medium (DMEM) supplemented with 10% 
(vol/vol) fetal bovine serum (FBS) and 1% antibiotic/antimycotic (Lonza) in 
a humidified incubator with 10% CO2. Stable HEK293T cells containing 
the WTFGFR2–GFP (GFP fused to the C terminus of WTFGFR2) were pro-
duced as described previously (Ahmed et al., 2008). In brief, the wild-type 
FGFR2 gene was cloned into a pEGFP-N2 vector, and transfection of 
the FGFR2 containing plasmid was done using Lipofectamine 2000 (Invitro-
gen) according to the manufacturer’s instructions. Stable cells were gener-
ated by G418 selection (1 mg/ml) for 2 wk with a change of medium 
every 4 d. The presence of the GFP tag has no discernible effect on FGFR2 
function (Lin et al., 2012). PC12 cells (European Collection of Cell Cultures 
accession no. 88022401) were cultured in DMEM supplemented with 
5% FBS and 10% horse serum and 1% antibiotic/antimycotic (Lonza) in 
a humidified incubator with 10% CO2 (Schüller et al., 2008). Control 
(Ci), Grb2, and Shp2 knockdown cells were generated by infecting 
designated cells with respective lentiviral particles. After 24 h infection, 
7 µg/ml puromycin was added and antibiotic-resistant cells were further 
expanded and used for experimentation. Mammalian cell transfection was 
performed in a 6-well plate using Metafectin reagents according to the 
manufacturer’s instructions.
Western blots
Cells were grown in 10-cm dishes, serum starved overnight, and stimu-
lated with either 10 ng/ml FGF2 or FGF9 for the indicated time period. 
regulation by Grb2. The major role of Grb2 with respect to 
FGFR2 therefore appears to be to stabilize the receptor mole-
cules in a predimerized state in which the prevailing phosphory-
lation state can be kept in check through restraining kinase 
activity toward downstream effector recruitment sites on the re-
ceptor and inhibiting recruitment of Shp2.
The control by Grb2 of FGFR2 and Shp2 activity is quite 
different to that reported for FGFR1, where Grb2 and Shp2 are 
downstream of FGFR substrate 2 (FRS2) and their recruitment 
only occurs after receptor activation and is dependent on FRS2 
phosphorylation (Hadari et al., 1998; Sato et al., 2010). To con-
firm this, FLIM was used to assess whether Grb2 was able to 
interact with FGFR1 in the same way observed for FGFR2 
(Ahmed et al., 2010). As expected, Grb2 interacts with FGFR2 
in HEK293T cells under nonstimulated conditions (Fig. S1 A), 
but has no discernible interaction with FGFR1 under the same 
conditions (Fig. S1 B). This differential recruitment of early sig-
naling protein suggests that the complex generated by FGFR2 
is significantly different from that which accompanies FGFR1. 
A further distinction between FGFR2 and FGFR1 can be observed 
in the recruitment of the key downstream effector FRS2. We 
had previously shown under nonstimulated conditions that 
unlike FGFR1, FGFR2 does not form a complex with FRS2 
Figure 8. Schematic diagram of cycle of enzymatic activity under the con-
trol of Grb2 in the absence of extracellular stimulation. (A) FGFR2 (blue) is 
stabilized in a basally phosphorylated state in the form of a heterotetramer 
in which a dimer of Grb2 recruits two receptor molecules. In this complex 
the receptors are able to autophosphorylate the activation loop tyrosines. 
The partially phosphorylated, nonsignaling state is represented by inclu-
sion of the green circle with dashed border. (B) Active Shp2 is able to 
dephopshorylate FGFR2. This phosphatase activity is inhibited by Grb2 
(red oval) when it is bound to the receptor. (C) Basally activated FGFR2 
is able to phosphorylate Shp2 phosphatase (orange). The phosphoryla-
tion of Shp2 is represented by a solid green line. On phosphorylation of 
Y542 Shp2 is enhanced. This catalytic activity is inhibited in the presence 
of Grb2 bound to FGFR2. The phosphorylated Shp2 is represented by 
inclusion of the green circle. (D) Grb2 is phosphorylated by FGFR2. In this 
phosphorylated state Grb2 is no longer able to bind to the receptor and 
hence its inhibitory properties are lost. (E) Shp2 is able to dephosphorylate 
Grb2. This restores the adaptor protein to a state competent of binding 
FGFR2. Key: straight lines between proteins represent the change from 
one state of that protein to another. Green lines, phosphorylation. Blue lines, 
dephosphorylation. Green dashed line, autophosphorylation. Red lines, 
inhibition. Curved arrows, enzymatic activity, e.g., blue line from Shp2 
intercepting dephosphorylation blue line between pFGFR and FGFR indi-
cates that Shp2 is the active enzyme for that change of state.
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with a single exponential decay model using SPCImage software (Becker 
& Hickl) and the GFP fluorescence lifetimes were displayed in a false-color 
map. The data shown are representative of three slides prepared from 
three independent experiments. For each image shown, n > 10 cells ana-
lyzed from each slide
In vitro FLIM
GFP-FGFR2 cytoplasmic domain (Cyto), RFP-Grb2, and histidine-tagged 
Shp2 were bacterially expressed and purified. 300 µl of Cyto at the final 
concentration of 2 µM in PBS buffer containing 10% glycerol was loaded 
onto a 35-mm glass-bottom dish (MatTek Corporation). The fluorescence 
lifetime was measured using an oil immersion objective at 20°C as de-
scribed above for FLIM, except the acquisition period was reduced to 120 s. 
RFP-Grb2 at final concentration of 2 µM was added to the Cyto mixture 
and allowed to equilibrate for 30 min (Fig. S4). The fluorescence lifetime 
of GFP-Cyto/RFP-Grb2 was recorded. 1 mM ATP/MgCl2 was then added 
to the reaction mixture, and after 30 min another recording of the fluor-
escence lifetime was performed. Shp2 was then added to the mixture at 
a final concentration of 2 µM and allowed to equilibrate for 20 min before 
adding 2 mM EDTA to the reaction. After 30 min of EDTA addition GFP-
Cyto lifetime was measured again. The reaction was then placed at 
4°C overnight (18 h) and a further GFP-Cyto lifetime was recorded. This 
procedure was repeated for the Y542F and C459S Shp2 mutants. The 
lifetime data were used to calculate the percentage of interacting mole-
cules (see Fig. S3).
Online supplemental material
Fig. S1 (A–C) shows FLIM data to demonstrate that Grb2 binds to FGFR2, 
but not FGFR1 or the oncogenic mutant S252WFGFR2. Fig. S1 (D–F) dem-
onstrates that FRS2 does not interact with FGFR2 in the nonstimulated 
state. Fig. S2 shows that the S252WFGFR2 mutant receptor is not constitu-
tively phosphorylated consistent with the absence of Grb2 inhibition. It also 
shows that when Shp2 is inhibited the phosphorylation of the receptor is 
restored to WTFGFR2 levels, suggesting that FGFR2 is a substrate the phos-
phatase, and in the background of WTFGFR2, Grb2 inhibits Shp2 activity. 
Fig. S3 (A) shows the fluorescence lifetime decay for GFP-FGFR2 and RFP-
Grb2. Fig. S3 (B–E) shows the FLIM fluorescence lifetime plots for the in vitro 
interaction of FGFR2 Grb2 and Shp2. These raw data were used to pro-
duce Fig. 7 C. Fig. S4 shows reduced FGF- and EGF-activated MAP kinase 
activation in cells with reduced Grb2 protein levels. Fig. S5 is a schematic 
representation of the enzymatic cycle of FGFR2 kinase and Shp2 phospha-
tase activity influenced by Grb2 under nonstimulated (Fig. S5 A) and ligand-
stimulated (Fig. S5 B) conditions.
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Cells were lysed with buffer containing 50 mM Hepes, pH 7.5, 1% (vol/vol) 
igepal-C630, 1 mg/ml bacitracin, 1 mM EDTA, 10 mM NaF, 1 mM sodium 
orthovanadate, 10% (vol/vol) glycerol, 50 mM NaCl, 1 mM PMSF, and 
Protease Inhibitor Cocktail Set III (EMD Millipore). The detergent-soluble 
fraction was used for Western blotting. Quantification of Western blots was 
done using ImageJ software.
Expression and purification of proteins from bacteria
Histidine-tagged fusion proteins were purified from BL21 (DE) cells. 10 ml 
of cells grown overnight were used to inoculate 1 liter of LB media loaded 
with 50 µg/ml kanamicin. The culture was allowed to grow with constant 
shaking (180 rpm) at 37°C until the OD600 = 0.6. At this point the culture 
was cooled down to 20°C before being induced by the addition of 300 µM 
IPTG. The culture was allowed to grow for a further 12 h before harvesting 
by centrifugation. Cells were resuspended in 50 mM Tris buffer at pH 8.0, 
containing 100 mM NaCl and 1 mM -ME, in the presence of protease 
inhibitors and lysed by sonication. Cell debris was removed by centrifuga-
tion (20,000 g at 4°C for 45 min). The soluble fraction was applied to an 
affinity column previously loaded with the above buffer followed by wash-
ing in 20 mM imidazole. Protein was eluted from the column with 200 mM 
imidazole and then concentrated to 5 ml before being applied to a Super-
dex SD75 gel filtration column loaded with 50 mM Tris buffer at pH 8.0, 
containing 100 mM NaCl and 1 mM -ME. Analysis of pure proteins 
on SDS-PAGE showed greater than 95% purity. N-terminal GFP-tagged 
FGFR2cyto, N-terminal RFP-tagged Grb2, Shp2 wild-type, and Shp2 mutants 
were expressed and purified using this protocol.
Fluorescence lifetime measurement
FRET fluorescence lifetime experiments to measure the formation of the 
complex between Grb2 and FGFR2 in the absence/presence of ATP/Mg2+ 
and Shp2 were performed in a spectrofluorometer (QuantaMaster-4-CW; 
Photon Technology International) at 23°C in 50 mM Tris-HCl at pH 8.5 
containing 100 mM NaCl, 1 mM -ME, and 5% glycerol. Phosphorylated 
C-terminal GFP-FGFR2cyto (donor) and N-terminal RFP-tagged Grb2 (accep-
tor) were mixed together in a 1:1 molar ratio to a final concentration of 
1 µM for each protein. Donor lifetime decay (FRET fluorescence lifetime) was 
recorded with the pulsed nitrogen laser operating under the following 
parameters: excitation, 488 nm; emission, 510 nm; start delay, 135 ns; end 
delay, 150 ns; channels, 200; integration time, 50 µs; averages, 3; shots, 5; 
frequency, 8 Hz. The fluorescence lifetime is based on the average time 
that a fluorophore takes to return to the ground state from its excited state 
after absorption of light. When the acceptor fluorophore is proximal to the 
donor such that FRET occurs, the lifetime of the fluorescing donor is short-
ened. As they dissociate the donor fluorescence lifetime increases. 500 µM 
of ATP/Mg2+ was added to the solution and lifetime measurements were 
taken at 20-min intervals up to 80 min. At the end of each time point EDTA 
was added to quench the reaction. Over this period the Grb2–FGFR2 
complex dissociated. At the 80-min time point Shp2 was added to the 
system to a final concentration of 1 µM. At this point the molar ratio of 
FGFR2cyto/Grb2/Shp2 was 1:1:1 because Grb2 and FGFR2 were di-
luted less than 3% after adding Shp2 to the solution. The fluorescence 
lifetime was then measured at 20-min intervals for 40 min to monitor the 
binding of Grb2 and FGFR2. Lifetime constants were calculated by fitting 
the decays using FeliX32 analysis software (Photon Technology Interna-
tional). A sample of raw data is shown in Fig. S3.
Cell imaging and FLIM
Cells were cotransfected with fluorescent protein-tagged proteins. Cells 
were grown on glass coverslips for 24–48 h before experimentation. Serum-
starved cells were either left untreated as basal or stimulated with 20 ng/ml 
FGF9 for the indicated time periods. Stimulation was stopped by addition 
of 4% (wt/vol) paraformaldehyde, pH 8.0. Cells were washed 6–7 times 
with PBS, pH 8.0, and then mounted onto a slide with mounting medium 
(0.1% p-phenylenediamine/75% glycerol in PBS at pH 7.5–8.0). Cells 
were imaged using a confocal microscope (model SP5; Leica) at 20°C. 
FLIM experiments were performed using an inverted advanced confocal 
microscope system (TCP SP5; Leica) with internal photomultiplier tube 
(PMT) detector for time-correlated single-photon counting (TCSPC). The 
sample was excited with a tunable femtosecond titanium-sapphire pumped 
laser (Mai Tai BB; Spectra-Physics). The wavelength used for two-photon 
excitation was 930 nm. Images were obtained with an oil-immersion 
objective (NA 1.4) and a line scan speed of 400 Hz, with image size of 
512 × 512 pixels. For FLIM analysis the pixels were reduced to 256 × 
256. FLIM data were collected using an SPC830 data and image acquisi-
tion card (Becker & Hickl) for TCSPC. The fluorescence decays were fitted 
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